Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 28;2013(2):CD007770.
doi: 10.1002/14651858.CD007770.pub2.

Oral H1 antihistamines as monotherapy for eczema

Christian J Apfelbacher  1 , Esther J van Zuuren, Zbys Fedorowicz, Aldrin Jupiter, Uwe Matterne, Elke Weisshaar
Affiliations

Oral H1 antihistamines as monotherapy for eczema

Christian J Apfelbacher et al. Cochrane Database Syst Rev. .

Abstract

Background: Eczema is a common skin disease in many countries, and although the majority of cases of eczema occur before the age of five years and often resolve during childhood or adolescence, it can also persist into adulthood. Itch is the most important aspect of eczema, often impacting significantly on the quality of life of an affected individual.

Objectives: To assess the effects of oral antihistamines (H1 antagonists) as monotherapy in children and adults with eczema.

Search methods: We searched the following databases up to March 2012: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library (2012, Issue 3), MEDLINE (from 1946), EMBASE (from 1974), and LILACS (from 1982). We examined the reference lists of excluded studies in order to identify further references to relevant trials. We searched trials registers for ongoing and unpublished trials. We also handsearched the abstracts of the International Research Workshops on eczema, as well as the conference proceedings of the European Academy of Dermatology and Venereology (EADV) and the European Academy of Allergology and Clinical Immunology (EAACI), from 2000 to 2011.

Selection criteria: We sought to include randomised controlled trials that assessed the effects and safety of oral H1 antihistamines as monotherapy in children and adults with eczema. We excluded studies that compared an antihistamine versus another antihistamine and had no placebo control arm. We also excluded topical antihistamines and oral H1 antihistamines as 'add-on' therapy and studies using any concomitant therapy other than emollients or moisturisers, principally because some of these forms of concomitant therapy may be considered treatment modifiers in assessments of the effects of antihistamines on eczema.

Data collection and analysis: Our search retrieved 409 references to studies. Based on assessments of their titles, abstracts, or both, we excluded all except 36 of these studies. After evaluation of the full text of each report, we excluded a further 35 studies, and 1 study is awaiting classification pending a response from the trial investigators.

Main results: No randomised controlled trials met our inclusion criteria.

Authors' conclusions: There is currently no high-level evidence to support or refute the efficacy or safety of oral H1 antihistamines used as monotherapy for eczema. Because most of the studies allowed the use of concomitant medications and involved multi-therapeutic approaches, meaningful assessments of the individual effects of oral H1 antihistamines on eczema were not feasible. Although well-designed randomised controlled trials excluding concomitant medications appear to be needed, consideration should be given to the potential ethical issues raised with the use of antihistamines as monotherapy for the management of eczema by withholding the use of rescue or additional therapies. A further systematic review of studies in which concomitant therapies were permitted might be of value in determining the potential benefits of oral H1 antihistamines as add-on therapy.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Flow diagram.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD007770

References

References to studies excluded from this review

Baraf 1976 {published data only}
    1. Baraf CS. Treatment of Pruritus in Allergic Dermatoses: An Evaluation of the Relative Efficacy of Cyproheptadine and Hydroxyzine. Current Therapeutic Research, Clinical & Experimental 1976;19(1):32‐8. [MEDLINE: ] - PubMed
Berth‐Jones 1989 {published data only}
    1. Berth‐Jones J, Graham‐Brown RA. Failure of terfenadine in relieving the pruritus of atopic dermatitis. British Journal of Dermatology 1989;121(5):635‐7. [MEDLINE: ] - PubMed
Castro Torres 1987 {published data only}
    1. Castro Torres A, Martin Moreno L, Jimenez Reyes J, Bucher Y. Double‐blind study terfenadine versus clemastine in pruriginous skin disorders [Terfenadina frente a clemastina en el tratamiento de las enfermedades cutáneas pruriginosas. Estudio comparativo doble‐ciego]. Revista Clinica Espanola 1987;181(8):410‐2. [MEDLINE: ] - PubMed
Doherty 1989 {published data only}
    1. Doherty V, Sylvester DG, Kennedy CT, Harvey SG, Calthrop JG, Gibson JR, et al. Treatment of itching in atopic eczema with antihistamines with a low sedative profile. BMJ 1989;298(6666):96. [MEDLINE: ] - PMC - PubMed
Falk 1993 {published data only}
    1. Falk ES. Ketotifen in the treatment of atopic dermatitis. Results of a double blind study. European Review for Medical & Pharmacological Sciences (Rivista Europea Per Le Scienze Mediche e Farmacologiche) 1993;15(2):63‐6. [MEDLINE: ] - PubMed
Foulds 1981 {published data only}
    1. Foulds IS, MacKie RM. A double‐blind trial of the H2 receptor antagonist cimetidine, and the H1 receptor antagonist promethazine hydrochloride in the treatment of atopic dermatitis. Clinical Allergy 1981;11(4):319‐23. [MEDLINE: ] - PubMed
Hamada 1996 {published data only}
    1. Hamada T, Ishii M, Nakagawa K, Kobayashi H, Kitajima J, Chanoki M, et al. Evaluation of the clinical effect of terfenadine in patients with atopic dermatitis. A comparison of strong corticosteroid therapy to mild topical corticosteroid combined with terfenadine administration therapy. Skin Research 1996;38(1):97‐103. [EMBASE: 1996118577]
Henz 1998 {published data only}
    1. Henz BM, Metzenauer P, O'Keefe E, Zuberbier T. Differential effects of new‐generation H1‐receptor antagonists in pruritic dermatoses. Allergy 1998;53(2):180‐3. [MEDLINE: ] - PubMed
Hjorth 1988 {published data only}
    1. Hjorth N. Terfenadine in the treatment of chronic idiopathic urticaria and atopic dermatitis. Cutis 1988;42(4A):29‐30. [MEDLINE: ] - PubMed
Kawashima 2003 {published data only}
    1. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1‐week randomized, multicentre, double‐blind, placebo‐controlled, parallel‐group study. British Journal of Dermatology 2003;148(6):1212‐21. [MEDLINE: ] - PubMed
Kawashima 2011 {published data only}
    1. Kawashima M, Nakagawa H. Olopatadine hydrochloride in children: Evidenced efficacy and safety for atopic dermatitis treatment in a randomized, multicenter, double‐blind, parallel group comparative study. Nishinihon Journal of Dermatology 2011;73(3):278‐89. [EMBASE: 2011412534]
Kimura 2009 {published data only}
    1. Kimura U, Matsuba S, Chikenji T, Haruna K, Kamano M, Suga, Y, et al. Usefulness of TARC in serum as treatment marker and combination treatment with loratadine and steroid ointment for atopic dermatitis. Skin Research 2009;8(2):125‐31. [EMBASE: 2010000252]
Klein 1980 {published data only}
    1. Klein GL, Galant SP. A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis. Annals of Allergy 1980;44(3):142‐5. [MEDLINE: ] - PubMed
Kuniyuki 2009 {published data only}
    1. Kuniyuki S, Yoshida Y, Maekawa N, Yamanaka K. Examination of olopatadine hydrochloride for anti‐itching and topical‐steroid sparing effects in patients with chronic eczema or dermatitis. Nishinihon Journal of Dermatology 2009;71(5):526‐30. [EMBASE: 2009581673]
La Rosa 1994 {published data only}
    1. Rosa M, Ranno C, Musarra I, Guglielmo F, Corrias A, Bellanti JA. Double‐blind study of cetirizine in atopic eczema in children. Annals of Allergy 1994;73(2):117‐22. [MEDLINE: ] - PubMed
Michel 1990 {published data only}
    1. Michel L, Vos C, Dubertret L. Cetirizine effects on the cutaneous allergic reaction in humans. Annals of Allergy 1990;65(5):512‐6. [MEDLINE: ] - PubMed
Monroe 1992 {published data only}
    1. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clinical Therapeutics 1992;14(1):17‐21. [MEDLINE: ] - PubMed
Munday 2002 {published data only}
    1. Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiezdziski Z, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology 2002;205(1):40‐5. [MEDLINE: ] - PubMed
Nakagawa 2006 {published data only}
    1. Nakagawa H, Kawashima M. Efficacy and safety of fexofenadine hydrochloride in pediatric patients with atopic dermatitis in a phase III, randomized, double‐blind, multi‐center comparative study. Nishinihon Journal of Dermatology 2006;68(5):553‐65. [EMBASE: 2006521484]
Nakayama 1980 {published data only}
    1. Nakayama Y, Akasaka T, Baba M, Iwasaki E, Funahashi S, Nishimuta T, et al. A double blind controlled trial of azatidine maleate syrup (idulamine syrup) in children with urticaria or atopic dermatitis. Comparison of effectiveness and side effect with d chlorpheniramine maleate syrup. Rinsho Hyoka: Clinical Evaluation 1980;8(1):235‐78. [CENTRAL: CN‐00268192]
Nuovo 1992 {published data only}
    1. Nuovo J, Ellsworth AJ, Larson EB. Treatment of Atopic Dermatitis With Antihistamines: Lessons from A Single‐Patient, Randomized Clinical Trial. Journal of the American Board of Family Practice 1992;5(2):137‐41. [MEDLINE: ] - PubMed
Patel 1997 {published data only}
    1. Patel P, Gratton D, Eckstein G, Aberer W, Pryzbilla B, Chelly M, et al. A double‐blind study of loratadine and cetirizine in atopic dermatitis. Journal of Dermatological Treatment 1997;8(4):249‐53. [EMBASE: 1998022646]
Ruzicka 1998 {published data only}
    1. Ruzicka T, Karmann B, Kowok K, Altmeyer P. Atopisches Ekzem: Behandlung mit Loratadin. Der Deutsche Dermatologe 1998;46(4):1‐8.
Savin 1979 {published data only}
    1. Savin JA, Paterson WD, Adam K, Oswald I. Effects of Trimeprazine and Trimipramine on Nocturnal Scratching in Patients with Atopic Eczema. Archives of Dermatology 1979;115(3):313‐5. [MEDLINE: ] - PubMed
Savin 1986 {published data only}
    1. Savin JA, Dow R, Harlow BJ, Massey H, Yee KF. The effect of a new non‐sedative H1‐receptor antagonist (LN2974) on the itching and scratching of patients with atopic eczema. Clinical & Experimental Dermatology 1986;11(6):600‐2. [MEDLINE: ] - PubMed
Sheng 2009 {published data only}
    1. Sheng N, Zong W‐K, Yu M‐W, Lin L, Cui P‐G. The clinical and immunological study of the mizolastine on the eczema and atopic dermatitis. Journal of Clinical Dermatology 2009;38(7):440‐2. [EMBASE: 2010312975]
Simons 2007 {published data only}
    1. Simons FE, Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18‐month study. Pediatric Allergy & Immunology 2007;18(6):535‐42. [MEDLINE: ] - PubMed
Sugai 2003 {published data only}
    1. Sugai J, Kakurai M, Otsuki M, Nakagawa H. Combination therapy with 0.1% tacrolimus ointment and cetirizine for facial atopic dermatitis [Abstract P2‐8]. The 12th Congress of the European Academy of Dermatology and Venereology, Barcelona, Spain 15‐18th October 2003. Journal of the European Academy of Dermatology & Venereology 2003;17(Suppl 3):174.
Tarchalska 1988 {published data only}
    1. Tarchalska B, Zawisza E. A new generation of antihistaminics (H1) [Nowa generacja leków przeciwhistaminowych (H1)]. Polski Tygodnik Lekarski 1988;43(51‐52):1672‐5. [MEDLINE: ] - PubMed
Tharp 1998 {published data only}
    1. Tharp MD, Lowe NJ, Soter N, Kramer B. A Double‐blind Parallel Study of Cetirizine (C) 20 mg and Placebo (P) in the Management of Patients with Atopic Dermatitis [P 41]. Annals of Allergy, Asthma, & Immunology 1998;80:110. [CENTRAL: CN‐00285014]
Tholen 1989 {published data only}
    1. Tholen S, Dieterich HA. Terfenadine versus ketotifen in children with atopic dermatitis [Terfendain versus ketotifen bei kindern mit atopischer dermatitis]. Allergologie 1989;12(2):60‐3. [EMBASE: 1989063112]
Wahlgren 1990 {published data only}
    1. Wahlgren CF, Hägermark O, Bergström R. The antipruritic effect of a sedative and a non‐sedative antihistamine in atopic dermatitis. British Journal of Dermatology 1990;122(4):545‐51. [MEDLINE: ] - PubMed
Wolfram 1967 {published data only}
    1. Wolfram S. Clinical experience with a new antihistaminic [Klinische Erfahrunge mit einem neuen Antihistaminikum]. Wiener Medizinische Wochenschrift 1967;117(38):868‐70. [MEDLINE: ] - PubMed
Zhang 1998 {published data only}
    1. Zhang SF, Zhang TD, Qiu XW, Zhan QS. 36 cases of terfenadine combining with IFN‐gamma for atopic dermatitis. Chinese Journal of Dermatovenereology 1998;12(2):85‐6.
Zimmermann 1981 {published data only}
    1. Zimmermann B, Fischer H. Antipruritic or anti‐allergic therapy. The efficacy and tolerance of intravenous dimethindenmaleate [Antipruriginöse bzw. antiallergische Therapie ‐ Zur Wirksamkeit und Verträglichkeit von Dimetindenmaleat bei intravenöser Verabreichung]. Fortschritte der Medizin 1981;99(35):1418‐20. [MEDLINE: ] - PubMed

References to studies awaiting assessment

Kircik 2010 {published data only}
    1. Kircik L. Management of pruritus with levocetirizine dihydrochloride in atopic dermatitis in a randomized, double‐blind, placebo controlled study ‐ Interim analysis of 21 subjects. Western Society of Allergy, Asthma, and Immunology Meeting Lnai, HI United States, 24‐28 January 2010. Allergy & Asthma Proceedings 2010;31(2):166. [EMBASE: 70168639]

Additional references

Brown 2006
    1. Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al. How to formulate research recommendations. BMJ 2006;333(7572):804‐6. [MEDLINE: ] - PMC - PubMed
Dawn 2009
    1. Dawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G. Itch characteristics in atopic dermatitis: results of a web‐based questionnaire. British Journal of Dermatology 2009;160(3):42‐4. [PUBMED: 19067703] - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. [PUBMED: 9310563] - PMC - PubMed
Engman 1936
    1. Engman M, Weiss R, Engman MJ. Eczema and environment. Medical Clinics of North America 1936;20:651‐63.
European Task Force on Atopic Dermatitis 1993
    1. No authors listed. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186(1):23‐31. [MEDLINE: ] - PubMed
Greaves 2001
    1. Greaves MW. Antihistamines. Dermatologic Clinics 2001;19(1):53‐62. [MEDLINE: ] - PubMed
Greaves 2005
    1. Greaves MW. Antihistamines in dermatology. Skin Pharmacology & Physiology 2005;18(5):220‐9. [PUBMED: 16015020] - PubMed
Handley 1998
    1. Handley DA, Magnetti A, Higgins AJ. Therapeutic advantages of third generation antihistamines. Expert Opinion on Investigational Drugs 1998;7(7):1045‐54. [MEDLINE: ] - PubMed
Hanifin 1980
    1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato‐Venereologica 1980;92(Suppl):44‐7.
Herman 2003
    1. Herman SM, Vender RB. Antihistamines in the treatment of dermatitis. Journal of Cutaneous Medicine & Surgery 2003;7(6):467‐73. [MEDLINE: ] - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Johansson 2004
    1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy & Clinical Immunology 2004;113(5):832‐6. [MEDLINE: ] - PubMed
Kay 2000
    1. Kay GG. The effects of antihistamines on cognition and performance. Journal of Allergy & Clinical Immunology 2000;105(6 Pt 2):S622‐7. [PUBMED: 10856168] - PubMed
Klein 1999
    1. Klein PA, Clark RA. An evidence‐based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Archives of Dermatology 1999;135(12):1522‐5. [MEDLINE: ] - PubMed
Odhiambo 2009
    1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy & Clinical Immunology 2009;124(6):1251‐8.e23. [PUBMED: 20004783] - PubMed
Reitamo 2001
    1. Reitamo S, Ansel JC, Luger TA. Itch in atopic dermatitis. Journal of the American Academy of Dermatology 2001;45(1 Suppl):S55‐6. [MEDLINE: ] - PubMed
Revman 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Rukwied 2000
    1. Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. British Journal of Dermatology 2000;142(6):1114‐20. [MEDLINE: ] - PubMed
Sackett 1989
    1. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95(2 Suppl):2S‐4S. [MEDLINE: ] - PubMed
Schmitt 2007
    1. Schmitt J, Langan S, Williams HC, European Dermato‐Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. Journal of Allergy and Clinical Immunology 2007;120(6):1389‐98. [PUBMED: PMID: 17910890] - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. [MEDLINE: ] - PubMed
Shaw 2011
    1. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. Journal of Investigative Dermatology 2011;131(1):67‐73. [PUBMED: 20739951] - PMC - PubMed
Thestrup‐Pedersen 2000
    1. Thestrup‐Pedersen K. Clinical aspects of atopic dermatitis. Clinical & Experimental Dermatology 2000;25(7):535‐43. [MEDLINE: ] - PubMed
Weisshaar 2006
    1. Weisshaar E, Apfelbacher A, Jäger G, Zimmermann E, Bruckner T, Diepgen T, et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. British Journal of Dermatology 2006;155(5):957‐64. [MEDLINE: ] - PubMed
Williams 1994
    1. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The UK Working Party's diagnostic criteria for atopic dermatitis. British Journal of Dermatology 1994;131(3):383‐96. [MEDLINE: ] - PubMed
Williams 2005
    1. Williams HC. Clinical practice. Atopic dermatitis. New England Journal of Medicine 2005;352(22):2314‐24. [MEDLINE: ] - PubMed
Woosley 1996
    1. Woosley RL. Cardiac actions of antihistamines. Annual Review of Pharmacology & Toxicology 1996;36:233‐52. [MEDLINE: ] - PubMed
Yanai 2012
    1. Yanai K, Rogala B, Chugh K, Paraskakis E, Pampura AN, Boev R. Safety considerations in the management of allergic diseases: focus on antihistamines. Current Medical Research & Opinion 2012;28(4):623‐42. [MEDLINE: ] - PubMed
Yosipovitch 2002
    1. Yosipovitch G, Goon AT, Wee J, Chan YH, Zucker I, Goh CL. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. International Journal of Dermatology 2002;41(4):212‐6. [MEDLINE: ] - PubMed
Zuberbier 2012
    1. Zuberbier T. Chronic Urticaria. Current Allergy Asthma Reports 2012;12(4):267‐72. [MEDLINE: ] - PubMed

Publication types

Substances